Lundbeck asked Hict for support in developing a budget impact analysis (BIA) for the reimbursement submission of Abilify Maintena®, a long-acting injectable drug for the maintenance treatment of schizophrenia.
The aim of the project for Hict was to provide support for the BIA and the price strategy.
In an intake phase, Hict determined the general strategy and the key elements of the BIA: identification of
In the subsequent phase, Hict was responsible for
In the intake phase, based on desk research and literature search, the most appropriate approach and strategy for the BIA in the reimbursement dossier of Abilify Maintena® was defined in cooperation with Lundbeck.
Second, the necessary data collection & processing was done based on desk research. An analysis of the reimbursement criteria of the comparators and existing market researches was performed, together with research on Belgian prevalence data, resource use and unit costs.
Subsequently, the BIA model was developed and populated with the collected Belgian data. A validation of the generated results was performed internally and with Lundbeck.
Finally, an extensive report was written, discussing in detail all aspects of the BIA model, together with the used data, values and sources. The report and the detailed BIA model was delivered and presented to Lundbeck.